Tilray Medical's German subsidiary will supply Luxembourg with high-quality medical cannabis following a government tender award.
Quiver AI Summary
Tilray Medical, part of Tilray Brands, Inc., has announced that its German subsidiary, Tilray Deutschland GmbH, has won a tender to supply Luxembourg with high-quality cannabis flower, granted by the Ministry of Health and Social Security. This opportunity reflects the confidence in Tilray Medical's capability to consistently deliver premium medical cannabis products, aligning with the growing demand in Europe. Denise Faltischek, the company's Chief Strategy Officer, expressed pride in the selection, acknowledging the team's commitment to providing high-quality products for patients globally. Tilray Medical continues to expand its presence in the international medical cannabis market, supplying a diverse portfolio of brands across multiple countries.
Potential Positives
- Tilray Medical's German subsidiary secured a tender to supply its high-quality cannabis flower to Luxembourg, demonstrating a successful expansion in the European market.
- The tender awarded by the Ministry of Health and Social Security of Luxembourg underscores the trust in Tilray Medical as a reliable supplier in the global medical cannabis industry.
- This accomplishment reflects Tilray's commitment to meeting the growing demand for premium medical cannabis products in Europe.
- The statement from Denise Faltischek emphasizes the dedication of Tilray's team to providing high-quality medical cannabis to patients worldwide.
Potential Negatives
- This press release emphasizes the need for Tilray Medical to secure tenders and contracts in competitive markets, indicating a reliance on external validation and contracts to succeed.
- The forward-looking statements included carry inherent risks and uncertainties that may impact the company's projected performance and growth, which could undermine investor confidence.
- There is no mention of financial details related to the tender, raising questions about the profitability and economic impact of this new contract for Tilray Medical.
FAQ
What recent achievement did Tilray Medical announce?
Tilray Medical's German subsidiary secured a tender to supply Luxembourg with high-quality cannabis flower.
Who awarded the tender to Tilray Deutschland GmbH?
The tender was awarded by the Ministry of Health and Social Security for the Grand Duchy of Luxembourg.
What does this tender signify for Tilray Medical?
This tender highlights Tilray Medical's capability to deliver high-quality medical cannabis consistently in the global market.
What is Tilray Medical's commitment in Europe?
Tilray Medical is committed to meeting Europe's growing demand for premium medical cannabis products.
Which brands are part of Tilray Medical's global portfolio?
Tilray Medical's portfolio includes brands like Broken Coast, Redecan, Good Supply, and Navcora.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TLRY Insider Trading Activity
$TLRY insiders have traded $TLRY stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TLRY stock by insiders over the last 6 months:
- CARL A MERTON (Chief Financial Officer) purchased 26,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TLRY Hedge Fund Activity
We have seen 122 institutional investors add shares of $TLRY stock to their portfolio, and 120 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 5,304,715 shares (+112.1%) to their portfolio in Q3 2024
- HIGHBRIDGE CAPITAL MANAGEMENT LLC added 2,207,100 shares (+74.0%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 1,851,375 shares (+inf%) to their portfolio in Q3 2024
- BNP PARIBAS FINANCIAL MARKETS added 1,690,827 shares (+1314.1%) to their portfolio in Q3 2024
- TIDAL INVESTMENTS LLC removed 1,306,242 shares (-11.9%) from their portfolio in Q3 2024
- PRENTICE CAPITAL MANAGEMENT, LP removed 1,291,616 shares (-92.8%) from their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 765,922 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEUMÜNSTER, Germany, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tilray Medical , a division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), proudly announces that its German subsidiary, Tilray Deutschland GmbH , has secured a tender to supply Luxembourg with its high-quality cannabis flower. The granting of this tender by the Ministry of Health and Social Security for the Grand Duchy of Luxembourg highlights the trust placed in Tilray Medical to deliver high-quality medical cannabis on a consistent basis across the global medical cannabis industry. Additionally, it reinforces Tilray’s commitment to deliver on Europe’s growing demand for premium medical cannabis products.
Denise Faltischek, Chief Strategy Officer and Head of International, said, "We are honored to have been selected again to supply medical cannabis to Luxembourg. This is a testament to the unwavering dedication of our team in providing patients around the world with high-quality medical cannabis products."
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments in over 20 countries and across five continents.
Further information can also be found here: Pioneering the Future of Medical Cannabis - Tilray EU
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information:
Media:
[email protected]
Investor Relations:
[email protected]